| __timestamp | ADMA Biologics, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 17763000 |
| Thursday, January 1, 2015 | 6745968 | 22180000 |
| Friday, January 1, 2016 | 8494742 | 37257000 |
| Sunday, January 1, 2017 | 18092835 | 27367000 |
| Monday, January 1, 2018 | 22502922 | 64770000 |
| Tuesday, January 1, 2019 | 25910757 | 74986000 |
| Wednesday, January 1, 2020 | 35050817 | 79256000 |
| Friday, January 1, 2021 | 42896889 | 100156000 |
| Saturday, January 1, 2022 | 52458024 | 131408000 |
| Sunday, January 1, 2023 | 59020000 | 152946000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding the financial dynamics of companies is crucial. Over the past decade, ADMA Biologics, Inc. and Dynavax Technologies Corporation have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics saw a steady increase in SG&A expenses, growing by approximately 1,100%. In contrast, Dynavax Technologies experienced a more dramatic rise, with expenses surging by nearly 760% during the same period. By 2023, Dynavax's SG&A expenses were more than double those of ADMA, highlighting its aggressive expansion strategy. This financial trajectory reflects each company's strategic priorities and market positioning. As the biotech sector continues to grow, monitoring these expenses provides valuable insights into operational efficiency and future growth potential.
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Insmed Incorporated vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.